Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

समान संसाधन

• A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
  द्वारा: Shima, Midori, और अन्य
  प्रकाशित: (2019)
• A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
  द्वारा: Yoneyama, Koichiro, और अन्य
  प्रकाशित: (2017)
• Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A
  द्वारा: Shima, Midori, और अन्य
  प्रकाशित: (2020)
• Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
  द्वारा: Yada, Koji, और अन्य
  प्रकाशित: (2019)
• Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
  द्वारा: Yada K, और अन्य
  प्रकाशित: (2019-07-01)